Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 245

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversion

Manns, Angela, Wilks, Rainford J., Murphy, Edward L., Haynes, Grace, Figueroa, J. Peter, Barnett, Marge, Hanchard, Barrie, Blattner, William A. · 1992 · International Journal of Cancer

Abstract

To evaluate the risk of transfusion‐related transmission of HTLV‐I in Jamaica, a prospective study was initiated, prior to availability of a licensed HTLV‐I serological screening assay. This information would prove useful in formulating strategies for blood‐donor screening. We followed 118 pre‐transfusion HTLV‐l‐negative transfusion recipients at monthly intervals posttransfusion for I year. Laboratory and questionnaire data were obtained at each visit to evaluate the clinical and immunological status of recipients. Cumulative incidence of HTLV‐I seroconversion was estimated and risk‐factor data associated with seroconversion among 66 HTLV‐l‐exposed transfusion recipients were analyzed. Seroconversion occurred in 24/54 (44%) of recipients of HTLV‐l‐positive cellular blood components, 0/12 recipients of positive non‐cellular donor units and 0/52 recipients of HTLV‐l‐negative donor units. Significant risk factors associated with recipient seroconversion were receipt of a seropositive cellular blood component stored for less than one week [odds ratio (OR) = 6.34, 95% confidence interval (CI) = 1.83 to 21.92], male sex (OR = 4.79, 95% CI = 1.15 to 20.0) or use of immunosuppressive therapy at time of transfusion (OR = 12.20, 95% CI = 0.95 to 156). Risk of blood‐borne infection per person per year in Jamaica was estimated to be 0.009%. Our results confirm that blood transfusion carries a significant risk of HTLV‐I transmission and that screening of donor blood effectively prevents HTLV‐I seroconversion. Recipients at greatest risk for seroconversion were those who required multiple transfusions or who were receiving immunosuppressive therapy at the time of transfusion. These patients should be given priority in receiving selectively screened blood components, if universal blood‐donor screening for HTLV‐I is not possible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.2910510609

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 245

Metadata

Authors
Manns, A., Wilks, R. J., Murphy, E. L., Haynes, G., Figueroa, J. P., Barnett, M., Hanchard, B., & Blattner, W. A.
Venue
International Journal of Cancer
Publisher
Wiley
Published
1992-07-30
Volume
51
Issue
6
Pages
886-891
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2166097710
Cited by
245
References
2
FWCI
2.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversion. https://app.cochat.ai/papers/10.1002/ijc.2910510609
The paper
Manns, A., Wilks, R. J., Murphy, E. L., Haynes, G., Figueroa, J. P., Barnett, M., Hanchard, B., & Blattner, W. A. (1992). A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversion. International Journal of Cancer. https://doi.org/10.1002/ijc.2910510609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.